NetScientific PLC portfolio company Glycotest has successfully closed a $1 million follow-on investment by Fosun Industrial Co., Limited, the fundraise was led by EMV Capital.
The proceeds of the Investment will, inter alia, support Glycotest in the development and validation of its assays ahead of commercial launch. Such validation is possible after the completion in 2023 of subject enrolment and sample collection in Glycotest’s clinical validation study, providing a valuable biobank which the company believes now represents one of the world’s largest collections of liver cancer blood samples.
This additional funding from Fosun demonstrates strong financial support as Glycotest continues to progress towards commercialisation, including in the US and China.
Read more here.